MHK
31
-3
PNC
53
-2
MNST
56
9
AMG
54
-4
FAST
46
-3
CA
25
-7
AVGO
88
27
FOX
68
-2
DIS
72
-5
KHC
22
2
WU
28
-4
MAR
62
-3
VMC
48
-2
CCL
68
-2
A
39
-2
MAS
52
-2
TROW
50
2
NSC
37
-3
UA
38
-9
CMCSA
39
-2
MHK
31
-3
PNC
53
-2
MNST
56
9
AMG
54
-4
FAST
46
-3
CA
25
-7
AVGO
88
27
FOX
68
-2
DIS
72
-5
KHC
22
2
WU
28
-4
MAR
62
-3
VMC
48
-2
CCL
68
-2
A
39
-2
MAS
52
-2
TROW
50
2
NSC
37
-3
UA
38
-9
CMCSA
39
-2
Financhill
Back

Silence Therapeutics PLC 10K Form

Sell
36

SLN
Silence Therapeutics PLC

Last Price:
6.50
Seasonality Move:
5.8%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SLN News And Ratings

See the #1 stock for the next 7 days that we like better than SLN

SLN Financial Statistics

Sales & Book Value

Annual Sales: $31.57M
Cash Flow: $-26.13M
Price / Cash Flow: 0
Annual Sales: $2.68
Price / Book: 2.46

Profitability

EPS (TTM): -1.68480
Net Income (TTM): $-75.06M
Gross Margin: $18.74M
Return on Equity: -79.63%
Return on Assets: -39.52%

Silence Therapeutics PLC Earnings Forecast

Key Silence Therapeutics PLC Financial Ratios

  • The Gross Profit Margin over the past 6 years for SLN is 59.34%.
  • The Selling, General & Administrative Expenses for SLN have been equal to 81.32% of Gross Profit Margin.
  • The Research & Development expenses have been 173.50% of Revenue.
  • The Interest Expense is -0.08% of Operating Income.
  • The Net Earning history of SLN is -170.51% of Total Revenues.
  • Per Share Earnings over the last 29 years have been positive in 15 years.

Silence Therapeutics PLC Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SLN
Website: silence-therapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 9.31
Quick Ratio: 8.61

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SLN Technical Analysis vs Fundamental Analysis

Sell
36
Silence Therapeutics PLC (SLN) is a Sell

Is Silence Therapeutics PLC a Buy or a Sell?